Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:52 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Not listed Phase 2 Interventional

Project RAP: Reaching Adolescents for Prevention

NCT00183157
View directory record Official record
Conditions
Alcohol Related Morbidity, Alcohol Dependence
Interventions
Brief Motivational Intervention, Assessment and list of resources, Referral to Community Resources
Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
14 Years to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 2 Interventional

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

NCT00413205
View directory record Official record
Conditions
Emphysema
Interventions
Placebo, RAR Gamma
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
44 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 3, 2026, 9:52 PM EST
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 3, 2026, 9:52 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Poweroff Sleep Study

NCT03364101
View directory record Official record
Conditions
Sleep
Interventions
Placebo Capsule, POWEROFF Capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Nov 3, 2026, 9:52 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 2 Interventional

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

NCT01779453
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

NCT05362695
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
View directory record Official record
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 2 Interventional Results available

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

NCT04835441
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ALPN-101, Placebo
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

NCT04060173
View directory record Official record
Conditions
Hyperuricemia, Gout
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Nov 3, 2026, 9:52 PM EST
Terminated Phase 3 Interventional Results available

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

NCT00637494
View directory record Official record
Conditions
Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions
mifepristone, placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
22 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Nov 3, 2026, 9:52 PM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

NCT00109772
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Type I
Interventions
lenalidomide, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Peoria, Arizona • La Jolla, California • Loma Linda, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Nov 3, 2026, 9:52 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Controlled Trial to Determine Most Effective Post-Operative Analgesia After Third Molar Extraction

NCT06484439
View directory record Official record
Conditions
Pain, Post-operative, Third Molar, Oral Surgery, Pain, Acute
Interventions
Ketorolac, Oxycodone, Acetaminophen, Ibuprofen, Hydrocodone
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 44 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 1 Interventional

Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

NCT04561258
View directory record Official record
Conditions
HIV
Interventions
AGT103-T
Biological
Lead sponsor
American Gene Technologies International Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Nov 3, 2026, 9:52 PM EST
Recruiting Phase 1 Interventional

Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue

NCT07498218
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
Interventions
an allogenic cell-based product, containing living human bone marrow-derived mesenchymal stem cells (MSCs) and MSCs differentiated into adipocytes on a porous chitosan-gelatin matrix, Standard of Care of Diabetic Foot Ulcers
Drug · Other
Lead sponsor
Ayu, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 9:52 PM EST
Not listed Phase 2 Interventional

Trial of Steroids in Pediatric Acute Lung Injury/ARDS

NCT01274260
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI)
Interventions
methylprednisolone, Normal Saline (0.9%)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218
View directory record Official record
Conditions
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Interventions
Lasmiditan, Alprazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790
View directory record Official record
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Nov 3, 2026, 9:52 PM EST
Terminated Phase 3 Interventional Results available

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

NCT01609582
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
TAK-875, TAK-875 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
3,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
218
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Nov 3, 2026, 9:52 PM EST
Completed No phase listed Observational

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

NCT00567723
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
2,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
199
States / cities
Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Nov 3, 2026, 9:52 PM EST
Completed Phase 4 Interventional Results available

Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959
View directory record Official record
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Nov 3, 2026, 9:52 PM EST
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 9:52 PM EST
Completed Not applicable Interventional

The Impact of Innovative Tax Proposals on Purchase Patterns

NCT05370313
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Market Price Condition (control), Tobacco Parity Tax Condition, Nicotine-Content Tax Condition, Harm-Reduction Tax Condition, Modified Risk Tobacco Product (MRTP) Tax Condition
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Buffalo, New York • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 3, 2026, 9:52 PM EST